Text Size

The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers

This study has been completed.
Sponsor:
Collaborator:
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00230269
First received: September 28, 2005
Last updated: July 10, 2012
Last verified: July 2012
History of Changes
  Purpose

In patients with cancer of the head and neck and rectum, knowing the exact location of the tumor is important for designing the radiation field to ensure delivery of high dose of radiation to the tumor while sparing surrounding normal tissues. A new medical imaging method which is a combination of positron emission tomography (PET) and computed tomography (CT) scan, has shown promise in helping the radiation oncologist in defining the exact location and extent of the tumor in certain cancers such as lung cancers. Therefore the purpose of this study is to determine if these imaging methods can be used in combination with the standard radiation treatment planning procedure to improve the accuracy to targeting your tumor with radiation. In addition the PET-CT scan, similar to the PET scan alone with better resolution, can be used to determine whether the tumor has spread to any part of the body outside of the head and neck sites.


Condition Intervention
Head and Neck Cancer
 Procedure: PET-CT

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Stanford University:

Enrollment: 5
Study Start Date: May 2003
Study Completion Date: November 2007
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who are scheduled to receive radiation therapy for head and neck cancer at Stanford.

Criteria

Inclusion Criteria:Patients who are scheduled to receive radiation therapy for head and neck cancer at Stanford.

Exclusion Criteria:Non-Stanford patients.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00230269

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Investigators
Principal Investigator: Quynh-Thu Le Stanford University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00230269     History of Changes
Other Study ID Numbers: ENT0005, ENT0005
Study First Received: September 28, 2005
Last Updated: July 10, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms

ClinicalTrials.gov processed this record on June 18, 2013